Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:40 - Any
Updated:8/30/2017
Start Date:September 2012
End Date:June 1, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
A combined molecular breast imaging / ultrasound system will enable coregistration of a
functional abnormality seen on Molecular Breast Imaging (MBI) with the corresponding
anatomical abnormality seen on ultrasound.


Inclusion Criteria:

- The pilot study will comprise 12 women age 40 and older who have at least one of the
following inclusion criteria:

1. Have a finding of a mass lesion on mammography or breast MRI (BIRADS 0, 4 or 5)
that is >0.5 cm and < 2 cm in size and has had or will have additional workup
with focused ultrasound.

2. Have a finding of a mass lesion on ultrasound (BIRADS 0, 4 or 5) that is > 0.5 cm
and < 2 cm in size.

3. Have a positive finding on MBI that is < 2 cm in size and requires additional
diagnostic workup with focused ultrasound.

Exclusion Criteria:

1. Are unable to understand and sign the consent form

2. Are pregnant or lactating

3. Are physically unable to sit upright and still for 40 minutes

4. Have undergone bilateral mastectomy

5. Are not scheduled to undergo conventional ultrasound
We found this trial at
1
site
The Mayo Clinic
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials